Literature DB >> 34733729

YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer.

Jia-Qi Yuan1, Ke-Jing Zhang1, Shou-Man Wang1, Lei Guo1.   

Abstract

BACKGROUND: To evaluate the association of potential YAP1/MMP7/CXCL16 axis and tumor infiltrating lymphocytes (TILs) related chemo-response in triple-negative breast cancer (TNBC) patients.
METHODS: We estimated the messenger RNA (mRNA) expression levels of Yes-associated protein 1 (YAP1), MMP7, and CXCL16 in paired TNBC tumor/para-tumor tissues by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), and performed statistical analysis according to neoadjuvant chemotherapy (NAC) response. Based on The Cancer Genome Atlas (TCGA) data, we noticed outstanding expression of MMP7/CXCL16 in TNBC cases, as well as associations between MMP7/CXCL16 and HIPPO-YAP1-relevant kinases. We also performed gene set enrichment analysis (GSEA) between MMP7/CXCL16 and YAP1-associated pathways. Western blotting assay was employed to evaluate YAP1/MMP7/CXCL16 expression in vitro and their modulation sequence. Logistic model stepwise regression analysis was used to assess YAP1, MMP7, CXCL16, and TILs as therapeutic predictors. Residual cancer burden (RCB) score was calculated and statistically analyzed according to intensity of these variables, and receiver operating characteristic (ROC) curve also showed their predictive value in NAC response. Recruitment efficacy for CD4+/CD8+ TIL cells (TCGA data) as well as quantified TIL cells density were both explored according to YAP1, MMP7, and CXCL16 expression level.
RESULTS: Up-regulation of YAP1/MMP7 and down-regulation of CXCL16 were both significant in TNBC cases with poor NAC response. Inhibition of YAP1 induced down-regulation of MMP7 and up-regulation of CXCL16, whereas inhibition of MMP7 also induced up-regulation of CXCL16. It was also shown that MMP7/CXCL16 was enriched in the YAP1-related pathway. Activation of the YAP1/MMP7/CXCL16 axis obviously affected RCB of TNBC cases. The ROC curve also supported the predictive value of YAP1/MMP7/CXCL16 axis and TILs density in NAC response prospect. The density of TILs, meanwhile, demonstrated a strong link with the YAP1/MMP7/CXCL16 axis. Over expression of YAP1/MMP7 significantly suppressed recruitment of CD4+/CD8+ TILs, while CXCL16 over expression had a beneficial impact on anti-tumor immune.
CONCLUSIONS: Over expression of causes up-regulation of MMP7 and down-regulation of CXCL16, which suppressed CD4+/CD8+ TILs recruitment and indirectly affected NAC response of TNBC patients. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Tumor-infiltrating lymphocyte (TILs); Yes-associated protein 1 (YAP1); matrix metalloproteinases (MMPs); neoadjuvant chemotherapy (NAC); triple negative breast cancer (TNBC)

Year:  2021        PMID: 34733729      PMCID: PMC8514296          DOI: 10.21037/gs-21-612

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  35 in total

1.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

Authors:  S Demaria; M D Volm; R L Shapiro; H T Yee; R Oratz; S C Formenti; F Muggia; W F Symmans
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 2.  The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Meteb E Al-Foheidi; Mubarak M Al-Mansour; Ghieth A Kazkaz
Journal:  Breast Cancer Res Treat       Date:  2014-11-01       Impact factor: 4.872

3.  The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT.

Authors:  Koji Hase; Takaya Murakami; Hiroyuki Takatsu; Takeshi Shimaoka; Mitsutoshi Iimura; Kimiyo Hamura; Kazuya Kawano; Sayaka Ohshima; Risa Chihara; Kikuji Itoh; Shin Yonehara; Hiroshi Ohno
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

4.  Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.

Authors:  W Mi; Q Lin; C Childress; M Sudol; J Robishaw; C H Berlot; M Shabahang; W Yang
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

5.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer.

Authors:  Shozo Hojo; Keiichi Koizumi; Koichi Tsuneyama; Yoshihisa Arita; Zhengguo Cui; Kanna Shinohara; Takayuki Minami; Isaya Hashimoto; Takashi Nakayama; Hiroaki Sakurai; Yasuo Takano; Osamu Yoshie; Kazuhiro Tsukada; Ikuo Saiki
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

8.  Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.

Authors:  Clémence Pinard; Marc Debled; Houda Ben Rejeb; Valérie Velasco; Christine Tunon de Lara; Stéphanie Hoppe; Elodie Richard; Véronique Brouste; Hervé Bonnefoi; Gaëtan MacGrogan
Journal:  Breast Cancer Res Treat       Date:  2019-09-16       Impact factor: 4.872

9.  A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.

Authors:  Mingyue Li; Shugang Xing; Haiying Zhang; Siqi Shang; Xiangxiang Li; Bo Ren; Gaiyun Li; Xiaona Chang; Yilei Li; Wei Li
Journal:  Oncol Rep       Date:  2016-01-05       Impact factor: 3.906

10.  A CT-based radiomics signature for evaluating tumor infiltrating Treg cells and outcome prediction of gastric cancer.

Authors:  Xujie Gao; Tingting Ma; Shuai Bai; Ying Liu; Yuwei Zhang; Yupeng Wu; Hui Li; Zhaoxiang Ye
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.